• Policy
• NHI coverage rate 64.5% in 2021...Fell 0.8% YOY
• by Lee, Tak-Sun Jan 11, 2023 05:59am

• Policy
• “Will dvlp blockbusters and systemize non-F2F treatment”
• by Lee, Jeong-Hwan Jan 10, 2023 05:35am

• Policy
• ↑63% of the average annual SA bill
• by Lee, Tak-Sun Jan 10, 2023 05:33am

• Policy
• nAMD & DME tx Vabysmo is about to be approved in Korea
• by Lee, Hye-Kyung Jan 9, 2023 06:10am

• Policy
• PMS standards lowered for Sanofi’s hemophilia drug
• by Lee, Hye-Kyung Jan 6, 2023 05:57am

• Policy
• Termination of PVA research services
• by Lee, Tak-Sun Jan 6, 2023 05:56am

• Policy
• Approval of Pfizer’s JAK inhibitor Xeljanz Srup imminent
• by Lee, Hye-Kyung Jan 4, 2023 05:32am

• Policy
• Koselugo is the only non-reimbursed drug among 21
• by Lee, Tak-Sun Jan 3, 2023 05:41am

• Policy
• The fast track of tx for serious dz without a substitute
• by Lee, Tak-Sun Jan 3, 2023 05:40am

• Policy
• Will Koselugo, a new neurofibroma drug be reimbursed next ye
• by Lee, Tak-Sun Jan 3, 2023 05:40am